What were the primary end points of the first trial discussed in the context?
The primary end point of the first trial discussed in the context was any bleeding and it was seen in 19.4% receiving double therapy and 44.4% receiving triple therapy (HR, 0.36; 95% CI, 0.26-0.50; P < .0001).